Targeting c-FLIP in cancer

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 141-150

  Shirley, Sarah ^a,b   Micheau, Olivier ^a,b,c  

^a Chu   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

C FLIP; Cancer; Death receptors

Indexed keywords

ANISOMYCIN; CASPASE 3; CASPASE 7; CISPLATIN; CYCLOHEXAMIDE; DACTINOMYCIN; FLICE INHIBITORY PROTEIN; FLUOROURACIL; GIVINOSTAT; PROTEIN SYNTHESIS INHIBITOR; SMALL INTERFERING RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID;

APOPTOSIS; CANCER CELL; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESEARCH; CANCER THERAPY; CELL SURVIVAL; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; RNA INTERFERENCE; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84876085177     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.009     Document Type: Review

References (121)

1. Hughes M.A., Harper N., Butterworth M., Cain K., Cohen G.M., MacFarlane M. Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival. Molecular Cell 2009, 35:265-279.
2. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
3. Micheau O. Cellular FLICE-inhibitory protein: an attractive therapeutic target?. Exp. Opin. Ther. Targets 2003, 7:559-573.
4. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
5. Chang L., Kamata H., Solinas G., Luo J.L., Maeda S., Venuprasad K., Liu Y.C., Karin M. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006, 124:601-613.
6. Micheau O., Thome M., Schneider P., Holler N., Tschopp J., Nicholson D.W., Briand C., Grutter M.G. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 2002, 277:45162-45171.
7. Wajant H., Haas E., Schwenzer R., Muhlenbeck F., Kreuz S., Schubert G., Grell M., Smith C., Scheurich P. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). J. Biol. Chem. 2000, 275:24357-24366.
8. Scaffidi C., Schmitz I., Krammer P.H., Peter M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 1999, 274:1541-1548.
9. Chang D.W., Xing Z., Pan Y., Algeciras-Schimnich A., Barnhart B.C., Yaish-Ohad S., Peter M.E., Yang X. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. Embo J. 2002, 21:3704-3714.
10. Hernandez A., Wang Q.D., Schwartz S.A., Evers B.M. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J. Gastrointest. Surg. 2001, 5:56-65.
11. Nam S.Y., Jung G.A., Hur G.C., Chung H.Y., Kim W.H., Seol D.W., Lee B.L. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci. 2003, 94:1066-1073.
12. Elnemr A., Ohta T., Yachie A., Kayahara M., Kitagawa H., Fujimura T., Ninomiya I., Fushida S., Nishimura G.I., Shimizu K., Miwa K. Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int. J. Oncol. 2001, 18:311-316.
13. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 1998, 161:2833-2840.
14. Xiao C.W., Yan X., Li Y., Reddy S.A., Tsang B.K. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology 2003, 144:623-630.
15. Zhang X., Jin T.G., Yang H., DeWolf W.C., Khosravi-Far R., Olumi A.F. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 2004, 64:7086-7091.
16. Olsson A., Diaz T., Aguilar-Santelises M., Osterborg A., Celsing F., Jondal M., Osorio L.M. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 2001, 15:1868-1877.
17. MacFarlane M., Harper N., Snowden R.T., Dyer M.J., Barnett G.A., Pringle J.H., Cohen G.M. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002, 21:6809-6818.
18. Korkolopoulou P., Goudopoulou A., Voutsinas G., Thomas-Tsagli E., Kapralos P., Patsouris E., Saetta A.A. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004, 63:1198-1204.
19. Salon C., Eymin B., Micheau O., Chaperot L., Plumas J., Brambilla C., Brambilla E., Gazzeri S. E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP (short). Cell Death Differ. 2006, 13:260-272.
20. Zong H., Yin B., Chen J., Ma B., Cai D., He X. Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma. Tohoku J. Exp. Med. 2009, 217:203-208.
21. Okano H., Shiraki K., Inoue H., Kawakita T., Yamanaka T., Deguchi M., Sugimoto K., Sakai T., Ohmori S., Fujikawa K., Murata K., Nakano T. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest. 2003, 83:1033-1043.
22. Lee S.H., Kim H.S., Kim S.Y., Lee Y.S., Park W.S., Kim S.H., Lee J.Y., Yoo N.J. Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. Apmis 2003, 111:309-314.
23. Zhou X.D., Yu J.P., Liu J., Luo H.S., Chen H.X., Yu H.G. Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma. Clin. Sci. (London) 2004, 106:397-405.
24. Mathas S., Lietz A., Anagnostopoulos I., Hummel F., Wiesner B., Janz M., Jundt F., Hirsch B., Johrens-Leder K., Vornlocher H.P., Bommert K., Stein H., Dorken B. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J. Exp. Med. 2004, 199:1041-1052.
25. Wilson N.S., Dixit V., Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 2009, 10:348-355.
26. Bullani R.R., Huard B., Viard-Leveugle I., Byers H.R., Irmler M., Saurat J.H., Tschopp J., French L.E. Selective expression of FLIP in malignant melanocytic skin lesions. J. Invest. Dermatol. 2001, 117:360-364.
27. de Hooge A.S., Berghuis D., Santos S.J., Mooiman E., Romeo S., Kummer J.A., Egeler R.M., van Tol M.J., Melief C.J., Hogendoorn P.C., Lankester A.C. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin. Cancer Res. 2007, 13:206-214.
28. Mori T., Doi R., Toyoda E., Koizumi M., Ito D., Kami K., Kida A., Masui T., Kawaguchi Y., Fujimoto K. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 2005, 138:71-77.
29. Djerbi M., Screpanti V., Catrina A.I., Bogen B., Biberfeld P., Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 1999, 190:1025-1032.
30. Ullenhag G.J., Mukherjee A., Watson N.F., Al-Attar A.H., Scholefield J.H., Durrant L.G. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res. 2007, 13:5070-5075.
31. Wang W., Wang S., Song X., Sima N., Xu X., Luo A., Chen G., Deng D., Xu Q., Meng L., Lu Y., Ma D. The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis. Gynecol. Oncol. 2007, 105:571-577.
32. Valnet-Rabier M.B., Challier B., Thiebault S., Angonin R., Margueritte G., Mougin C., Kantelip B., Deconinck E., Cahn J.Y., Fest T. c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br. J. Haematol. 2005, 128:767-773.
33. Valente G., Manfroi F., Peracchio C., Nicotra G., Castino R., Nicosia G., Kerim S., Isidoro C. cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy. Br. J. Haematol. 2006, 132:560-570.
34. Duiker E.W., van der Zee A.G., de Graeff P., Boersma-van Ek W., Hollema H., de Bock G.H., de Jong S., de Vries E.G. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol. Oncol. 2010, 116:549-555.
35. Longley D.B., Wilson T.R., McEwan M., Allen W.L., McDermott U., Galligan L., Johnston P.G. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006, 25:838-848.
36. Micheau O., Solary E., Hammann A., Dimanche-Boitrel M.T. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem. 1999, 274:7987-7992.
37. Micheau O., Lens S., Gaide O., Alevizopoulos K., Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol. Cell Biol. 2001, 21:5299-5305.
38. Kreuz S., Siegmund D., Scheurich P., Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell Biol. 2001, 21:3964-3973.
39. Bartke T., Siegmund D., Peters N., Reichwein M., Henkler F., Scheurich P., Wajant H. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 2001, 20:571-580.
40. Borrelli S., Candi E., Alotto D., Castagnoli C., Melino G., Vigano M.A., Mantovani R. p63 regulates the caspase-8-FLIP apoptotic pathway in epidermis. Cell Death Differ. 2009, 16:253-263.
41. Skurk C., Maatz H., Kim H.S., Yang J., Abid M.R., Aird W.C., Walsh K. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J. Biol. Chem. 2004, 279:1513-1525.
42. Mahalingam D., Natoni A., Keane M., Samali A., Szegezdi E. Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Br. J. Cancer 2010, 102:754-764.
43. Ganapathy M., Ghosh R., Jianping X., Zhang X., Bedolla R., Schoolfield J., Yeh I.T., Troyer D.A., Olumi A.F., Kumar A.P. Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin. Cancer Res. 2009, 15:1601-1611.
44. Gao S., Wang H., Lee P., Melamed J., Li C.X., Zhang F., Wu H., Zhou L., Wang Z. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J. Mol. Endocrinol. 2006, 36:463-483.
45. Ricci M.S., Jin Z., Dews M., Yu D., Thomas-Tikhonenko A., Dicker D.T., El-Deiry W.S. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell Biol. 2004, 24:8541-8555.
46. Hu G., Barnes B.J. IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J. Biol. Chem. 2009, 284:2767-2777.
47. Li W., Zhang X., Olumi A.F. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res. 2007, 67:2247-2255.
48. Ueffing N., Schuster M., Keil E., Schulze-Osthoff K., Schmitz I. Up-regulation of c-FLIP short by NFAT contributes to apoptosis resistance of short-term activated T cells. Blood 2008, 112:690-698.
49. Chen L.C., Chung I.C., Hsueh C., Tsang N.M., Chi L.M., Liang Y., Chen C.C., Wang L.J., Chang Y.S. The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients. Cell Death Differ. 2010.
50. O. Micheau, Cellular FLICE-inhibitory protein: an update, in: P.D.D.S.F. Klaus-Michael Debatin (Ed.), Apoptosis and Cancer Therapy, 2008, pp. 120-156.
51. Hennino A., Berard M., Casamayor-Palleja M., Krammer P.H., Defrance T. Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. J. Immunol. 2000, 165:3023-3030.
52. Travert M., Ame-Thomas P., Pangault C., Morizot A., Micheau O., Semana G., Lamy T., Fest T., Tarte K., Guillaudeux T. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J. Immunol. 2008, 181:1001-1011.
53. Wilson C., Wilson T., Johnston P.G., Longley D.B., Waugh D.J. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol. Cancer Ther. 2008, 7:2649-2661.
54. Zhang X., Li W., Olumi A.F. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Clin. Cancer Res. 2007, 13:7181-7190.
55. Zhang X., Zhang L., Yang H., Huang X., Otu H., Libermann T.A., DeWolf W.C., Khosravi-Far R., Olumi A.F. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res. 2007, 67:9425-9434.
56. Troeger A., Schmitz I., Siepermann M., Glouchkova L., Gerdemann U., Janka-Schaub G.E., Schulze-Osthoff K., Dilloo D. Up-regulation of c-FLIPS+R upon CD40 stimulation is associated with inhibition of CD95-induced apoptosis in primary precursor B-ALL. Blood 2007, 110:384-387.
57. Rushworth S.A., Taylor A., Langa S., MacEwan D.J. TNF signaling gets FLIPped off: TNF-induced regulation of FLIP. Cell Cycle 2008, 7:194-199.
58. Fulda S., Meyer E., Debatin K.M. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res. 2000, 60:3947-3956.
59. Tran S.E., Meinander A., Holmstrom T.H., Rivero-Muller A., Heiskanen K.M., Linnau E.K., Courtney M.J., Mosser D.D., Sistonen L., Eriksson J.E. Heat stress downregulates FLIP and sensitizes cells to Fas receptor-mediated apoptosis. Cell Death Differ. 2003, 10:1137-1147.
60. Fukazawa T., Fujiwara T., Uno F., Teraishi F., Kadowaki Y., Itoshima T., Takata Y., Kagawa S., Roth J.A., Tschopp J., Tanaka N. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 2001, 20:5225-5231.
61. Poukkula M., Kaunisto A., Hietakangas V., Denessiouk K., Katajamaki T., Johnson M.S., Sistonen L., Eriksson J.E. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J. Biol. Chem. 2005, 280:27345-27355.
62. Panner A., Crane C.A., Weng C., Feletti A., Parsa A.T., Pieper R.O. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res. 2009, 69:7911-7916.
63. Jin Z., Li Y., Pitti R., Lawrence D., Pham V.C., Lill J.R., Ashkenazi A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137:721-735.
64. Sanchez-Perez T., Ortiz-Ferron G., Lopez-Rivas A. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ. 2010, 17:883-894.
65. Son Y.G., Kim E.H., Kim J.Y., Kim S.U., Kwon T.K., Yoon A.R., Yun C.O., Choi K.S. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res. 2007, 67:8274-8284.
66. Zou W., Chen S., Liu X., Yue P., Sporn M.B., Khuri F.R., Sun S.Y. c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. Cancer Biol. Ther. 2007, 6:1614-1620.
67. Kaunisto A., Kochin V., Asaoka T., Mikhailov A., Poukkula M., Meinander A., Eriksson J.E. PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability. Cell Death Differ. 2009, 16:1215-1226.
68. Shi B., Tran T., Sobkoviak R., Pope R.M. Activation-induced degradation of FLIP(L) is mediated via the phosphatidylinositol 3-kinase/Akt signaling pathway in macrophages. J. Biol. Chem. 2009, 284:14513-14523.
69. Kundu M., Pathak S.K., Kumawat K., Basu S., Chatterjee G., Pathak S., Noguchi T., Takeda K., Ichijo H., Thien C.B., Langdon W.Y., Basu J. A TNF- and c-Cbl-dependent FLIP(S)-degradation pathway and its function in Mycobacterium tuberculosis-induced macrophage apoptosis. Nat. Immunol. 2009, 10:918-926.
70. Wang L., Azad N., Kongkaneramit L., Chen F., Lu Y., Jiang B.H., Rojanasakul Y. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J. Immunol. 2008, 180:3072-3080.
71. Nakano H., Nakajima A., Sakon-Komazawa S., Piao J.H., Xue X., Okumura K. Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ. 2006, 13:730-737.
72. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., Borden E.C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2004, 11:915-923.
73. Galligan L., Longley D.B., McEwan M., Wilson T.R., McLaughlin K., Johnston P.G. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol. Cancer Ther. 2005, 4:2026-2036.
74. Song J.H., Song D.K., Herlyn M., Petruk K.C., Hao C. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin. Cancer Res. 2003, 9:4255-4266.
75. Abedini M.R., Muller E.J., Brun J., Bergeron R., Gray D.A., Tsang B.K. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res. 2008, 68:4511-4517.
76. Abedini M.R., Muller E.J., Bergeron R., Gray D.A., Tsang B.K. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 2010, 29:11-25.
77. Yang B.F., Xiao C., Roa W.H., Krammer P.H., Hao C. Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells. J. Biol. Chem. 2003, 278:7043-7050.
78. Park S.J., Kim M.J., Kim H.B., Sohn H.Y., Bae J.H., Kang C.D., Kim S.H. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem. Pharmacol. 2009, 77:1328-1336.
79. Pathil A., Armeanu S., Venturelli S., Mascagni P., Weiss T.S., Gregor M., Lauer U.M., Bitzer M. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology (Baltimore, Md) 2006, 43:425-434.
80. Perez L.E., Parquet N., Shain K., Nimmanapalli R., Alsina M., Anasetti C., Dalton W. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J. Immunol. 2008, 180:1545-1555.
81. Mezzanzanica D., Balladore E., Turatti F., Luison E., Alberti P., Bagnoli M., Figini M., Mazzoni A., Raspagliesi F., Oggionni M., Pilotti S., Canevari S. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin. Cancer Res. 2004, 10:5202-5214.
82. Thomas R.K., Kallenborn A., Wickenhauser C., Schultze J.L., Draube A., Vockerodt M., Re D., Diehl V., Wolf J. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am. J. Pathol. 2002, 160:1521-1528.
83. Mawji I.A., Simpson C.D., Gronda M., Williams M.A., Hurren R., Henderson C.J., Datti A., Wrana J.L., Schimmer A.D. A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res. 2007, 67:8307-8315.
84. Lacour S., Micheau O., Hammann A., Drouineaud V., Tschopp J., Solary E., Dimanche-Boitrel M.T. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003, 22:1807-1816.
85. Zhao X., Qiu W., Kung J., Peng X., Yegappan M., Yen-Lieberman B., Hsi E.D. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leukemia Res. 2008, 32:275-285.
86. Koschny R., Holland H., Sykora J., Haas T.L., Sprick M.R., Ganten T.M., Krupp W., Bauer M., Ahnert P., Meixensberger J., Walczak H. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin. Cancer Res. 2007, 13:3403-3412.
87. Koschny R., Holland H., Sykora J., Erdal H., Krupp W., Bauer M., Bockmuehl U., Ahnert P., Meixensberger J., Stremmel W., Walczak H., Ganten T.M. Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. J. Neurooncol. 2010, 97:171-185.
88. Riccioni R., Senese M., Diverio D., Riti V., Buffolino S., Mariani G., Boe A., Cedrone M., Lo-Coco F., Foa R., Peschle C., Testa U. M4 and M5 acute myeloid leukaemias display a high sensitivity to bortezomib-mediated apoptosis. Br. J. Haematol. 2007, 139:194-205.
89. Perez L.E., Parquet N., Meads M., Anasetti C., Dalton W. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur. J. Haematol. 2010, 84:212-222.
90. Balsas P., Lopez-Royuela N., Galan-Malo P., Anel A., Marzo I., Naval J. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem. Pharmacol. 2009, 77:804-812.
91. Liu X., Yue P., Chen S., Hu L., Lonial S., Khuri F.R., Sun S.Y. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007, 67:4981-4988.
92. Melino G., Knight R.A., Cesareni G. Degradation of p63 by itch. Cell Cycle 2006, 5:1735-1739.
93. Gregory M.A., Hann S.R. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol. Cell Biol. 2000, 20:2423-2435.
94. Tsurumi C., Ishida N., Tamura T., Kakizuka A., Nishida E., Okumura E., Kishimoto T., Inagaki M., Okazaki K., Sagata N., et al. Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Mol. Cell Biol. 1995, 15:5682-5687.
95. Plas D.R., Thompson C.B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem. 2003, 278:12361-12366.
96. Kinoshita H., Yoshikawa H., Shiiki K., Hamada Y., Nakajima Y., Tasaka K. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int. J. Cancer 2000, 88:986-991.
97. White-Gilbertson S.J., Kasman L., McKillop J., Tirodkar T., Lu P., Voelkel-Johnson C. Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins. J. Urol. 2009, 182:1178-1185.
98. El-Zawahry A., McKillop J., Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 2005, 5:2.
99. Zhang G., Park M.A., Mitchell C., Hamed H., Rahmani M., Martin A.P., Curiel D.T., Yacoub A., Graf M., Lee R., Roberts J.D., Fisher P.B., Grant S., Dent P. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin. Cancer Res. 2008, 14:5385-5399.
100. Wood T.E., Dalili S., Simpson C.D., Sukhai M.A., Hurren R., Anyiwe K., Mao X., Suarez Saiz F., Gronda M., Eberhard Y., MacLean N., Ketela T., Reed J.C., Moffat J., Minden M.D., Batey R.A., Schimmer A.D. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol. Cancer Ther. 2010, 9:246-256.
101. Wang P., Zhang J., Bellail A., Jiang W., Hugh J., Kneteman N.M., Hao C. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 2007, 19:2237-2246.
102. Chatterjee D., Goldman M., Braastad C.D., Darnowski J., Wyche J.H., Pantazis P., Goodglick L. Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta. Int. J. Oncol. 2004, 25:503-509.
103. Tomek S., Horak P., Pribill I., Haller G., Rossler M., Zielinski C.C., Pils D., Krainer M. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol. Oncol. 2004, 94:107-114.
104. Murtaza I., Saleem M., Adhami V.M., Hafeez B.B., Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res. 2009, 69:1156-1165.
105. Sung B., Park B., Yadav V.R., Aggarwal B.B. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J. Biol. Chem. 2010, 285:11498-11507.
106. Takada Y., Murakami A., Aggarwal B.B. Zerumbone abolishes NF-kappaB and IkappaBalpha kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. Oncogene 2005, 24:6957-6969.
107. Lee T.J., Um H.J., Min do S., Park J.W., Choi K.S., Kwon T.K. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic. Biol. Med. 2009, 46:1639-1649.
108. Jani T.S., Devecchio J., Mazumdar T., Agyeman A., Houghton J.A. Inhibition of NF-{kappa}B signaling by quinacrine is cytotoxic to human colon carcinoma cell lines (cc) and is synergistic in combination with TRAIL or oxaliplatin. J. Biol. Chem. 2010.
109. Li X., Huang Q., Ong C.N., Yang X.F., Shen H.M. Chrysin sensitizes tumor necrosis factor-alpha-induced apoptosis in human tumor cells via suppression of nuclear factor-kappaB. Cancer Lett. 2010, 293:109-116.
110. Petronelli A., Pannitteri G., Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009, 20:880-892.
111. Day T.W., Safa A.R. RNA interference in cancer: targeting the anti-apoptotic protein c-FLIP for drug discovery. Mini Rev. Med. Chem. 2009, 9:741-748.
112. Hernandez A., Thomas R., Smith F., Sandberg J., Kim S., Chung D.H., Evers B.M. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001, 130:265-272.
113. Ganten T.M., Koschny R., Haas T.L., Sykora J., Li-Weber M., Herzer K., Walczak H. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology (Baltimore, Md) 2005, 42:588-597.
114. Plissonnier M.L., Fauconnet S., Bittard H., Lascombe I. Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells. Int. J. Cancer 2010.
115. Grund K., Ahmadi R., Jung F., Funke V., Gdynia G., Benner A., Sykora J., Walczak H., Joos S., Felsberg J., Reifenberger G., Wiestler O.D., Herold-Mende C., Roth W. Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. Cancer Biol. Ther. 2008, 7:1982-1990.
116. Schultze K., Bock B., Eckert A., Oevermann L., Ramacher D., Wiestler O., Roth W. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and survivin. Apoptosis 2006, 11:1503-1512.
117. Llobet D., Eritja N., Yeramian A., Pallares J., Sorolla A., Domingo M., Santacana M., Gonzalez-Tallada F.J., Matias-Guiu X., Dolcet X. The multikinase inhibitor sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur. J. Cancer 2010, 46:836-850.
118. Katz S.I., Zhou L., Chao G., Smith C.D., Ferrara T., Wang W., Dicker D.T., El-Deiry W.S. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol. Ther. 2009, 8:2406-2416.
119. Day T.W., Najafi F., Wu C.H., Safa A.R. Cellular FLICE-like inhibitory protein (c-FLIP): a novel target for taxol-induced apoptosis. Biochem. Pharmacol. 2006, 71:1551-1561.
120. Siegelin M.D., Siegelin Y., Habel A., Gaiser T. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis. Neurosci. Lett. 2009, 453:92-97.
121. Liu X., Yue P., Schonthal A.H., Khuri F.R., Sun S.Y. Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res. 2006, 66:11115-11119.